Why Ketamine Immobilizes Some Users

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-10T20:39:28.787Z • Permanent link

Ketamine has long been used as an anesthetic, but recent studies have shed light on its potential as a treatment for depression and anxiety. According to a 2020 study published in the Journal of Psychopharmacology, ketamine was found to be effective in reducing symptoms of depression in patients who had not responded to traditional treatments. This has led to increased interest in the use of ketamine for mental health treatment, particularly among researchers and clinicians.

The pharmaceutical company, Allergan, has been at the forefront of ketamine research. In 2019, the company announced plans to launch a new ketamine-based medication, Spravato, for the treatment of treatment-resistant depression. Spravato has been approved by the FDA and is currently available in the US. However, its use has been met with controversy due to concerns over its potential for abuse and the need for close monitoring.

Despite the controversy, ketamine's potential as a treatment for mental health conditions has been recognized by leading researchers and institutions. Dr. Michael Borson, a psychiatrist at the University of Pennsylvania, has been a vocal advocate for the use of ketamine in treating depression. He has stated that ketamine has the potential to revolutionize the treatment of mental health conditions, particularly for patients who have not responded to traditional treatments.

The impact of ketamine on the AI & Tech Ecosystems domain cannot be overstated. Companies such as IBM and Google are already exploring the use of ketamine as a potential treatment for depression and anxiety. IBM has partnered with the University of Pennsylvania to develop a ketamine-based treatment for depression, while Google has filed patents for a ketamine-based medication for the treatment of mental health conditions.

The research community is also taking notice of ketamine's potential. A 2020 study published in the journal Nature Medicine found that ketamine was effective in reducing symptoms of depression in patients with treatment-resistant depression. The study was conducted by a team of researchers at the University of California, San Francisco, and was funded by the National Institutes of Health.

As the use of ketamine becomes more widespread, it is likely to have a significant impact on the markets and policy environments surrounding mental health treatment. Companies such as Eli Lilly and Pfizer are already developing ketamine-based medications, and it is likely that these medications will be subject to rigorous testing and regulation.